Actively Recruiting
Phase 1 Study of Asciminib as Maintenance Therapy After Stem Cell Transplant or CAR T Therapy to Prevent Relapse in Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-03-27
36
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and appropriate dosing of a drug called asciminib for adults who have been treated for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph B-ALL. The study focuses on two groups those who have had an allogeneic stem cell transplant alloHCT and those who have received chimeric antigen receptor T cell CAR T therapy. This phase 1 study aims to find the best dose of asciminib to prevent relapse in these patients. Participants will receive asciminib treatment on an outpatient basis after their previous therapy with either alloHCT or CAR T cell therapy. The study includes two experimental groups one for patients post-alloHCT and another for patients post-CAR T therapy. Treatment will be carefully monitored to determine the recommended dose for future studies. During the study, researchers will regularly assess participants health, including survival without relapse and overall survival, for up to 24 months. They will monitor organ function, disease status, and any side effects. Participants progress will be tracked to evaluate the safety and effectiveness of asciminib maintenance therapy over time.
CONDITIONS
Brief Title
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
Research Team
V
Valerie Trujillo
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here